Regeneron (REGN) Misses Q4 EPS by 48c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Stocks end near flat as investors assess earnings, data
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Roth Affirms Regeneron (REGN) at 'Buy' Following Q4 Results; Sees Opportunity in Shares on Pullback
February 10, 2016 11:53 AM ESTRoth Capital reaffirmed Regeneron (Nasdaq: REGN) at Buy with a price target of $555 after the company reported Q4 EPS of $2.83 and revenue of $1.1 billion, versus consensus estimates calling for EPS of $3.31 and revenue of $1.17 billion, this week.
Analyst Joseph Pantginis commented: REGN's shares have not been immune to the enhanced market turbulence surrounding... More
Leerink Partners Cuts Price Target on Regeneron (REGN) as Eylea Growth Slows
February 10, 2016 8:30 AM ESTLeerink Partners maintained an Outperform rating on Regeneron Pharma (NASDAQ: REGN), and cut the price target to $505.00 (from $534.00), following the company's 4Q earnings report. REGN reported weaker than expected 4Q results with soft Eylea growth and guidance, and lower total revenue and pro forma EPS. Regenerons Q4 Eylea revenue had been previously... More
Baird Cuts Price Target on Regeneron (REGN) as Late Stage Trials Hit Operating Costs - Reiterates Outperform
February 9, 2016 1:45 PM ESTBaird maintained an Outperform rating on Regeneron Pharma (NASDAQ: REGN), and cut the price target to $526.00 (from $674.00), following the company's 4Q. Non-GAAP EPS missed consensus at $2.81 compared to $3.38. Revenues were lower than expected at $1.10B versus consensus estimates of $1.17B. Mirroring REGN's pre-release in January, U.S.... More
